News & Updates

A cross-sectional analysis has found an association between insomnia, poor sleep quality, and extremes of sleep duration and increased COVID-19 infection and hospitalization.

In the treatment of patients with programmed cell death ligand 1 (PD-L1)-positive, unresectable, and locally advanced nonsmall cell lung cancer (NSCLC), the use of durvalumab immunotherapy in combination with curative radiotherapy yields survival gains with tolerable adverse events (AEs), as shown in the results of the phase II DOLPHIN trial.

Perioperative nivolumab plus platinum-based chemotherapy improves pathological complete response (pCR) rate and survival outcomes vs neoadjuvant platinum-based chemotherapy alone in patients with resectable stage IIIA/B non-small-cell lung cancer (NSCLC), results of the NADIM II trial have shown.

Epidermal growth factor receptor (EGFR)-mothers against decapentaplegic homologue 7 (SMAD7)-Chimeric antigen receptor (CAR) T-cell therapy against nonsmall-cell lung cancer (NSCLC) is on a par with EGFR-dominant‒negative transforming growth factor (TGFbeta) receptor 2 (DNR)-CAR-T in terms of efficacy and resistance to negative TGFβ regulation, a study has shown.

Severe airflow limitation tends to contribute to future muscle wasting in patients with chronic obstructive pulmonary disease (COPD) and ever-smokers at risk of COPD, reports a recent study.

In patients admitted to the intensive care unit (ICU) for severe community-acquired pneumonia (CAP), those who received hydrocortisone had a lower mortality risk compared with those on placebo, findings from the CAPE COD* trial suggest.